Skip to main content

Table 1 Clinicopathologic features of published cases with de novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements

From: De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a case report and literature review

Case (ref. n) Age/sex Extramedullary lesion at presentation CNS FAB criteria Immunophenotype Main cytogenetic abnormalities FISH or gene analysis Curative therapy Survival
CD10 CD19 CD20 sIg IGH-BCL2 MYC  
1 (8) 57/F bone + L3 + + – ND t(8;22)(q24;q12a),t(14;18)(q32;q21) NA NA ALL regimen 7 mo
2 (9) 74/M palate, L (cervical, pretracheal) – L3 NA + NA μ t(8;22)(q24;q11),t(14;18)(q32;q21) NA NA ALL regimen 3 mo
3 (9) 37/M none – L2 – + + IgMλ t(8;22)(q24;q11),t(14;18)(q32;q21) NA NA ALL regimen 12 mo
4 (9) 73/M none + L3 + + + IgMκ t(8;22)(q24;q11),t(14;18)(q32;q21) NA NA ALL regimen 8 mo
5 (10) 62/M H, S – L3 + + + ND t(8;14)(q24;q32),t(14;18)(q32;q21) NA NA ALL regimen 3 mo
6 (11) 35/M none – L3 + + NA ND t(14;18)(q32;q21) GR (+) GR (+) ALL regimen 0.3 mo
7 (12) 27/M L (IP, RP) + L3 + + – ND t(8;22)(q24;q11),der(14)t(14;18)(q32;q21) NA NA ALL regimen 5 mo
8 (13) 67/M none – L3 NA + + IgGκ t(8;22)(q24;q11),t(14;18)(q32;q21) NA NA none 0.1 mo
9 (14) 71/M none – L3 −/+ + + IgMλ t(1;3;11)(q42.3;q27.1;q23.1),der(8)t(8;9)(q24.2;p13.3),t(14;18)(q32.3;q21.3),der(17)t(17;?)(p13;?) GR (+) GR (+) none 0.1 mo
10 (15) 36/F IP mass – NA + + NA ND t(8;22)(q24;q11),t(14;18)(q32;q21) NA GR (−) ALL regimen 3 mo
11 (15) 60 M none + L2 NA NA NA NA t(8;22)(q24;q11),t(14;18)(q32;q21),+der(14)t(14;18)(q32;q21) NA GR (−) ALL regimen 6 mo
12 (16) 40/M GL, paravertebral mass – L2 + + + NA der(6)t(6;8)(q1?;q24),add(8)(q24),der(9)t(8;9)(q24;p1?),t(14;18)(q32;q21),del(17)(p11) NA NA ALL regimen 1 mo
13 (17) 69/M H – L3 – + + IgMκ der(7;17)(q10;q10),+der(8)t(8;14;18)(q24;q32;q22),add(14)(q32),del(18)(q21) GR (+) NA ALL regimen 5 mo
14 (18) 41/F none – L3 + + + NA t(2;3)(p12;q27),del(8)(q24),t(14;18)(q32;q21) GR (+) GR (+) ALL regimen 10 mo
15 (19) 50/F GL – L2 + + + IgMκ t(3;4)(q27;p13),t(8;14;18)(q24;q32;q21),+ider(8)(q10)t(8;14;18)(q24;q32;q21) GR (+) GR (+) ALL regimen 0.1 mo
16 (19) 44/M GL, S + NA + + + IgMκ t(3;13)(q27;q14),t(8;22)(q24;q11),t(14;18)(q32;q21),+der(18)t(14;18)(q32;q21) GR (+) GR (−) NCVBP, IVAM, ASCT 7 mo
17 (19) 46/F GL, S, Asc, PE + L2 + + + IgMκ t(2;3)(p12;q27),add(8)(q24),der(14)t(8;14)(q24;q32),der(18)t(14;18)(q32;q21) GR (+) GR (+) ACVBP, allo-SCT 3 mo
18 (20) 62/F none NA L3 NA NA NA NA t(2;8)(p12;q24),t(14;18)(q32;q21) NA NA none 0.1 mo
19 (21) 48/M GL – L2 NA NA NA NA t(8;9)(q24,p13),t(14;18)(q32;q21) NA NA R-CHOP 3.5 mo
20 (22) 72/M H, S – L2 + NA + IgGκ t(8;9)(q24;p13),t(14;18)(q32;q21) NA NA R-EPOCH 4 mo
21 (23) 71/M S (mild) – L2 – + + γ t(1;2)(q22–23;p13),t(8;14)(q24;q32),t(14;18)(q32;q22) GR (+) GR (+) ALL regimen 2 mo
22 (24) 50/F L (axillary), SC mass – L3 + + NA ND t(2;3)(p12;q27),t(8;22)(q24;q11),t(14;18)(q32;q21),-17 fusion (+) split (+) ALL regimen 7 mo
23 (25) 29/M none – L3 + + + NA +8,t(8;22)(q24;q11),t(14;18)(q32;q21) NA split (+) R-CHOP, R-ICE, R-hyper-CVAD/MA 5 mo
24 (25) 72/M none – L3 + + + NA t(8;22)(q24;q11.2),t(14;18)(q32;q21) NA NA R-hyper-CVAD/MA 11 mob
25 (25) 50/F none + L3 + + + NA t(8;22)(q24;q11),t(14;18)(q32;q21) fusion (+) split (+) R-hyper-CVAD/MA 3 mo
26 (25) 32/M L (mesenteric) + L3 + + + NA t(1;3)(p32;q26.2),t(8;22)(q24;q11),add(14)(q32),t(14;18)(q32;q21) fusion (+) split (+) hyper-CVAD/MA 8 mo
27 (25) 67/M L (P), small intestine + L3 + + + NA t(8;14)(q24;q32),der(8)t(8;14)t(14;18)(q32;q21),der(14)t(8;14),+add(14)(q32),i(17)(q10) fusion (+) split (+) R-hyper-CVAD/MA, velcade 9 mo
28 (25) 61/M L (RP), colon, prostate + L3 NA NA NA NA t(8;22)(q24;q11),t(14;18)(q32;q21),+der(14)t(14;18) fusion (+) NA hyper-CVAD/MA, MOAP 9 mo
29 (25) 42/F small intestine, omentum, breast – L3 + + + NA t(8;14)(q24;q32),t(14;18)(q32;q21),der(17)t(10;17)(q22;q10) fusion (+) NA proMACECytaBOM, CHOP, ESHAP, hyper-CVAD/MA, SCT, RT 12 mo
30 (25) 63/M testis, lip – L3 + + + NA NA fusion (+) split (+) hyper-CVAD 18 mo
31 (26) 57/F none NA NA + + – NA der(3)t(3;14;?)(q27;q32;?),t(8;14)(q24;q32),der(18)t(14;18)(q32;q21) fusion (+) split (+) CODOX-M/IVAC 2.5 mo
32 (26) 60/M none NA L3 + + + D t(2;8)(p12;q24),der(8)t(2;8)(p12;q24),t(14;18)(q32;q21),?i(17)(q10) fusion (+) split (+) hyper-CVAD, CODOX-M 3 mo
33 (26) 63/M GL, S (mild) NA L3 + + + D der(3)t(1;3)(q23;q27),t(8;22)(q24;q11),t(14;18)(q32;q21) fusion (+) split (+) CODOX-M/IVAC 6 mo
34 (26) 76/F none NA L3 – + NA D t(8;22)(q24,q11),t(14;18)(q32;q21) fusion (+) split (+) VAD 6 mo
35 (26) 59/F none NA L2 + NA NA NA t(8;9)(q24;p13),t(14;18)(q32;q21) fusion (+) split (+) ALL regimen 1.5 mo
36 (26) 69/M L (IP), H NA L3 + + + D t(14;18)(q32;q21) fusion (+) split (+) ALL regimen 1.5 mo
37 (26) 86/F none NA L2 + + + ND add(9)(p13),t(14;18)(q32;q21) fusion (+) split (+) none 0.5 mo
38 (27) 43/F pancreas + L3 + + + IgMλ t(8;14)(q24;q32),t(14;18)(q32;q21) fusion (+) split (+) R-CODOX-M/IVAC 5 mo
39 (28) 61/M GL, S, PE – L3 + + + γ t(3;5)(q27;q15),t(8;14;18)(q24;q32;q21),+der(8)t(8;14;18),+der(18)t(8;14;18) fusion (+) split (+) R-hyper-CVAD, NAc
40 (29) 42/M L (IP), S + L2 + + + κ der(8)del(8)(q12.1q12.3)del(8)(q24.21q24.21)t(8;12)(q24.21;p12.1),der(12)del(12)(p12.1p12.1)t(8;12)(q24.21;p12.1),t(14;18)(q32;q21) fusion (+) split (+) R-CHOP, ALL regimen 7 mo
41 (30) 72/M bone, liver + NA + NA + NA t(3;8)(q27;q24),t(14;18)(q32;q21) fusion (+) split (+) ALL regimen NAc
42 (31) 64/M L (NA) – NA + NA + NA NA fusion (+) split (+) R-EPOCH 1.7 moc
43 (31) 72/M L (NA) – NA + NA + NA t(3;22)(q27;q11.2),t(8;14)(q24;q32),t(14;18)(q32;q21) fusion (+) split (+) R-EPOCH 1.6 moc
44 (32) 74/F none + L2 + + + κ –8,del(11)(q23q25),del(13)(q12q14),t(14;18)(q32;q21),+18 fusion (+) split (+) R-CHOP 3 mo
45 (32) 67/M colon – L3 + + −/+ κ NA fusion (+) split (+) R-CHOP 11 mod
46 (32) 71/M L (mediastinal) – L3 + + + κ der(8)t(8;14;18)(q24;q32;q21),der(14)t(8;14)(q24.1;q32),der(18)t(14;18)(q32;q21) fusion (+) split (+) R-EPOCH, R-ICE, ASCT 14 mo
47 (33) 60/M GL NA L2 + + + λ +8,inv(8)(p11.2q24)×2,t(14;18)(q32;q21),-17 fusion (+) split (+) R-hyperCVAD, ofatumumab + EPOCH 18 mo
48 (present case) 69/F none – L2 + + + IgMκ add(8)(q24),t(14;18)(q32;q21),-17 fusion (+) split (+), EC (+) R-hyper-CVAD/MA, R-EPOCH 7 mo
  1. Abbreviations: Ref n reference number, FAB criteria blastoid cell morphology according to the French-American-British classification, CNS development of central nervous system involvement, sIg surface immunoglobulin, M male, F female, L lymphadenopathy, H hepatomegaly, S splenomegaly, SC subcutaneous, IP intraperitoneal, RP retroperitoneal, GL generalized lymphadenopathy, Asc ascites, PE pleural effusion, P pelvic, ND not detected, D detected, NA not available, GR gene rearrangement, EC extra copies, ALL regimen multidrug chemotherapy for acute lymphoblastic leukemia, NCVBP mitoxantrone, cyclophosphamide, vinblastine, bleomycin, and prednisone, IVAM ifosfamide, etoposide, cytarabine, and methotrexate, ASCT autologous stem cell transplantation, ACVBP doxorubicin, cyclophosphamide, vinblastine, bleomycin, and prednisone, allo-SCT allogeneic stem cell transplantation, R rituximab, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, EPOCH etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, ICE ifosfamide, carboplatin, and etoposide, hyper-CVAD/MA cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with methotrexate and cytarabine, MOAP methotrexate, vincristine, asparaginase, and prednisone, proMACEcytaBOM prednisone, vincristine, methotrexate, doxorubicin, cyclophosphamide, etoposide, cytarabine, and bleomycin, ESHAP etoposide, methylprednisolone, cytarabine, and cisplatin, RT radiation therapy, CODOX-M/IVAC cyclophosphamide, vincristine, doxorubicin, methotrexate alternating with ifosfamide, etoposide, and cytarabine, VAD vincristine, doxorubicin, and dexamethasone, POMP prednisone, vincristine, methotrexate, and mercaptopurine
  2. aThis description is according to original work [8]
  3. bAlive (disease status was not described)
  4. cAlive with disease at the time of publication
  5. dAlive with no evidence of disease at the time of publication
Back to article page

BMC Clinical Pathology

ISSN: 1472-6890

Contact us

\